Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004

Keizo Yamaguchi, Yoshikazu Ishii, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Akira Suwabe, Kumiko Yamahata, Mitsuo Kaku, Keiji Kanemitsu, Hiroshi Yoshida, Kyouko Nishiyama, Masami Murakami, Ayako Takahashi, Kouichi Itoh, Tomoko Oohara, Fumio Nomura, Masaharu Watanabe, Harushige KannoMasanori Aihara, Shigefumi Maesaki, Giichi Hashikita, Kazunori Miyake, Toyoko Oguri, Jun Okada, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Masahiko Okada, Sugako Kobayashi, Toshinobu Horii, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Toshiaki Komori, Satoshi Ichiyama, Shigetaka Maeda, Kiyoharu Yamanaka, Yoko Murata, Masaru Komatsu, Shohiro Kinoshita, Tomohiko Taminato, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuchika Kusano, Euchiro Mihara, Masayuki Kambe, Hideyuki Itaha, Junko Ono, Hisae Yoshimura, Yoichi Hirakata, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC 90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-β-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC 90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 μg/ml→1 μg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.

Original languageEnglish
Pages (from-to)655-689
Number of pages35
JournalJapanese Journal of Antibiotics
Volume58
Issue number6
Publication statusPublished - Dec 2005

Fingerprint

meropenem
Anti-Bacterial Agents
Pseudomonas aeruginosa
Carbapenems
Anaerobic Bacteria
Imipenem
Haemophilus influenzae
Gram-Positive Bacteria
Enterobacteriaceae
Gram-Negative Bacteria
Citrobacter koseri
Peptostreptococcus
Enterobacter cloacae
Proteus mirabilis
Serratia marcescens
Klebsiella pneumoniae
Methicillin-Resistant Staphylococcus aureus
Ciprofloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Yamaguchi, K., Ishii, Y., Iwata, M., Watanabe, N., Uehara, N., Yasujima, M., ... Hiramatsu, K. (2005). Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Japanese Journal of Antibiotics, 58(6), 655-689.

Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. / Yamaguchi, Keizo; Ishii, Yoshikazu; Iwata, Morihiro; Watanabe, Naoki; Uehara, Nobuyuki; Yasujima, Minoru; Kasai, Takeshi; Suwabe, Akira; Yamahata, Kumiko; Kaku, Mitsuo; Kanemitsu, Keiji; Yoshida, Hiroshi; Nishiyama, Kyouko; Murakami, Masami; Takahashi, Ayako; Itoh, Kouichi; Oohara, Tomoko; Nomura, Fumio; Watanabe, Masaharu; Kanno, Harushige; Aihara, Masanori; Maesaki, Shigefumi; Hashikita, Giichi; Miyake, Kazunori; Oguri, Toyoko; Okada, Jun; Tazawa, Yoko; Nakashima, Hideki; Takemura, Hiromu; Okada, Masahiko; Kobayashi, Sugako; Horii, Toshinobu; Baba, Hisashi; Ishigo, Shiomi; Fujita, Naohisa; Komori, Toshiaki; Ichiyama, Satoshi; Maeda, Shigetaka; Yamanaka, Kiyoharu; Murata, Yoko; Komatsu, Masaru; Kinoshita, Shohiro; Taminato, Tomohiko; Negayama, Kiyoshi; Murase, Mitsuharu; Miyamoto, Hitoshi; Kusano, Nobuchika; Mihara, Euchiro; Kambe, Masayuki; Itaha, Hideyuki; Ono, Junko; Yoshimura, Hisae; Hirakata, Yoichi; Matsuda, Junichi; Saikawa, Tetsunori; Hiramatsu, Kazufumi.

In: Japanese Journal of Antibiotics, Vol. 58, No. 6, 12.2005, p. 655-689.

Research output: Contribution to journalArticle

Yamaguchi, K, Ishii, Y, Iwata, M, Watanabe, N, Uehara, N, Yasujima, M, Kasai, T, Suwabe, A, Yamahata, K, Kaku, M, Kanemitsu, K, Yoshida, H, Nishiyama, K, Murakami, M, Takahashi, A, Itoh, K, Oohara, T, Nomura, F, Watanabe, M, Kanno, H, Aihara, M, Maesaki, S, Hashikita, G, Miyake, K, Oguri, T, Okada, J, Tazawa, Y, Nakashima, H, Takemura, H, Okada, M, Kobayashi, S, Horii, T, Baba, H, Ishigo, S, Fujita, N, Komori, T, Ichiyama, S, Maeda, S, Yamanaka, K, Murata, Y, Komatsu, M, Kinoshita, S, Taminato, T, Negayama, K, Murase, M, Miyamoto, H, Kusano, N, Mihara, E, Kambe, M, Itaha, H, Ono, J, Yoshimura, H, Hirakata, Y, Matsuda, J, Saikawa, T & Hiramatsu, K 2005, 'Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004', Japanese Journal of Antibiotics, vol. 58, no. 6, pp. 655-689.
Yamaguchi, Keizo ; Ishii, Yoshikazu ; Iwata, Morihiro ; Watanabe, Naoki ; Uehara, Nobuyuki ; Yasujima, Minoru ; Kasai, Takeshi ; Suwabe, Akira ; Yamahata, Kumiko ; Kaku, Mitsuo ; Kanemitsu, Keiji ; Yoshida, Hiroshi ; Nishiyama, Kyouko ; Murakami, Masami ; Takahashi, Ayako ; Itoh, Kouichi ; Oohara, Tomoko ; Nomura, Fumio ; Watanabe, Masaharu ; Kanno, Harushige ; Aihara, Masanori ; Maesaki, Shigefumi ; Hashikita, Giichi ; Miyake, Kazunori ; Oguri, Toyoko ; Okada, Jun ; Tazawa, Yoko ; Nakashima, Hideki ; Takemura, Hiromu ; Okada, Masahiko ; Kobayashi, Sugako ; Horii, Toshinobu ; Baba, Hisashi ; Ishigo, Shiomi ; Fujita, Naohisa ; Komori, Toshiaki ; Ichiyama, Satoshi ; Maeda, Shigetaka ; Yamanaka, Kiyoharu ; Murata, Yoko ; Komatsu, Masaru ; Kinoshita, Shohiro ; Taminato, Tomohiko ; Negayama, Kiyoshi ; Murase, Mitsuharu ; Miyamoto, Hitoshi ; Kusano, Nobuchika ; Mihara, Euchiro ; Kambe, Masayuki ; Itaha, Hideyuki ; Ono, Junko ; Yoshimura, Hisae ; Hirakata, Yoichi ; Matsuda, Junichi ; Saikawa, Tetsunori ; Hiramatsu, Kazufumi. / Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. In: Japanese Journal of Antibiotics. 2005 ; Vol. 58, No. 6. pp. 655-689.
@article{8a9a8c23b3a44f038b3613675f2d091b,
title = "Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004",
abstract = "The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC 90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9{\%}). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2{\%}) and ciprofloxacin-resistant P. aeruginosa (38.0{\%}). 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1{\%} (4 strains) in Escherichia coli, 8.0{\%} (2 strains) in Citrobacter koseri, 2.5{\%} (3 strains) in Klebsiella pneumoniae, 2.5{\%} (2 strains) in Enterobacter cloacae, 0.9{\%} (1 strains) in Serratia marcescens, and 2.2{\%} (2 strains) in Proteus mirabilis. The proportion of metallo-β-lactamase strains was 1.6{\%} (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC 90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 μg/ml→1 μg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.",
author = "Keizo Yamaguchi and Yoshikazu Ishii and Morihiro Iwata and Naoki Watanabe and Nobuyuki Uehara and Minoru Yasujima and Takeshi Kasai and Akira Suwabe and Kumiko Yamahata and Mitsuo Kaku and Keiji Kanemitsu and Hiroshi Yoshida and Kyouko Nishiyama and Masami Murakami and Ayako Takahashi and Kouichi Itoh and Tomoko Oohara and Fumio Nomura and Masaharu Watanabe and Harushige Kanno and Masanori Aihara and Shigefumi Maesaki and Giichi Hashikita and Kazunori Miyake and Toyoko Oguri and Jun Okada and Yoko Tazawa and Hideki Nakashima and Hiromu Takemura and Masahiko Okada and Sugako Kobayashi and Toshinobu Horii and Hisashi Baba and Shiomi Ishigo and Naohisa Fujita and Toshiaki Komori and Satoshi Ichiyama and Shigetaka Maeda and Kiyoharu Yamanaka and Yoko Murata and Masaru Komatsu and Shohiro Kinoshita and Tomohiko Taminato and Kiyoshi Negayama and Mitsuharu Murase and Hitoshi Miyamoto and Nobuchika Kusano and Euchiro Mihara and Masayuki Kambe and Hideyuki Itaha and Junko Ono and Hisae Yoshimura and Yoichi Hirakata and Junichi Matsuda and Tetsunori Saikawa and Kazufumi Hiramatsu",
year = "2005",
month = "12",
language = "English",
volume = "58",
pages = "655--689",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "6",

}

TY - JOUR

T1 - Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004

AU - Yamaguchi, Keizo

AU - Ishii, Yoshikazu

AU - Iwata, Morihiro

AU - Watanabe, Naoki

AU - Uehara, Nobuyuki

AU - Yasujima, Minoru

AU - Kasai, Takeshi

AU - Suwabe, Akira

AU - Yamahata, Kumiko

AU - Kaku, Mitsuo

AU - Kanemitsu, Keiji

AU - Yoshida, Hiroshi

AU - Nishiyama, Kyouko

AU - Murakami, Masami

AU - Takahashi, Ayako

AU - Itoh, Kouichi

AU - Oohara, Tomoko

AU - Nomura, Fumio

AU - Watanabe, Masaharu

AU - Kanno, Harushige

AU - Aihara, Masanori

AU - Maesaki, Shigefumi

AU - Hashikita, Giichi

AU - Miyake, Kazunori

AU - Oguri, Toyoko

AU - Okada, Jun

AU - Tazawa, Yoko

AU - Nakashima, Hideki

AU - Takemura, Hiromu

AU - Okada, Masahiko

AU - Kobayashi, Sugako

AU - Horii, Toshinobu

AU - Baba, Hisashi

AU - Ishigo, Shiomi

AU - Fujita, Naohisa

AU - Komori, Toshiaki

AU - Ichiyama, Satoshi

AU - Maeda, Shigetaka

AU - Yamanaka, Kiyoharu

AU - Murata, Yoko

AU - Komatsu, Masaru

AU - Kinoshita, Shohiro

AU - Taminato, Tomohiko

AU - Negayama, Kiyoshi

AU - Murase, Mitsuharu

AU - Miyamoto, Hitoshi

AU - Kusano, Nobuchika

AU - Mihara, Euchiro

AU - Kambe, Masayuki

AU - Itaha, Hideyuki

AU - Ono, Junko

AU - Yoshimura, Hisae

AU - Hirakata, Yoichi

AU - Matsuda, Junichi

AU - Saikawa, Tetsunori

AU - Hiramatsu, Kazufumi

PY - 2005/12

Y1 - 2005/12

N2 - The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC 90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-β-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC 90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 μg/ml→1 μg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.

AB - The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC 90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-β-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC 90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 μg/ml→1 μg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.

UR - http://www.scopus.com/inward/record.url?scp=31444444651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444444651&partnerID=8YFLogxK

M3 - Article

C2 - 16521347

AN - SCOPUS:31444444651

VL - 58

SP - 655

EP - 689

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 6

ER -